Practical Manual of Clinical Obesity

Aim: There is evidence that the body mass index (BMI) is related, to some extent, to the quality of life (QoL) in different populations. The purpose of our study was to investigate the differences in QoL in relation to the BMI in patients awaiting coronary angiography. Method: The sample consisted of 100 patients (68 males and 32 females) with symptoms indicating coronary angiography. For all of them BMI was calculated. The participants completed the Duke Health profile questionnaire (DUKE) which measures adult self-reported functional health status. Results: After splitting the group in two according to the BMI median cut-off point, the findings reveal differences in the following aspects of

show abstract

“…In the Practical Manual of Clinical Obesity, authors Kushner, Lawrence, and Kumar (2013) say the following:…”

mentioning

confidence: 99%

Body Mass Index and Quality of Life in Patients Waiting for Coronary Angiography: A Pilot Study

Dojcinovski¹,

Naumoska²,

Ristovska³

et al. 2014

Psychol. Community Health

View full text Add to dashboard Cite

show abstract

Section: Obesity Prevalencementioning

confidence: 99%

“…It is generally understood that obesity is a multifactorial problem with modifiable and non-modifiable risk factors (CDC, 2015;Rippe & Angelopoulos, 2012;Kushner, Lawrence, Kumar & Lau, 2013). Excessive calorie intake, inadequate energy expenditure, and genetic predisposition in the right combination are theorized to result in obesity (CDC, 2015;Rippe & Angelopoulos, 2012;Kushner et al, 2013). This may combine with extraneous factors such as stress (Torres & Nowson, 2007), food access (Wolters & Steel, 2016), and environmental chemicals (Tang-Pernonard, Andersen, Jensen & Heitmann, 2011) to increase the risk of morbid weight gain.…”

Section: Obesity Prevalencementioning

confidence: 99%

“…Pharmacotherapy for obesity, however, is not utilized as often as most guidelines recommend (Kahan, 2016). This may be related to past safety concerns with early weight loss drugs (Rippe & Angelopoulos, 2012;Kushner et al, 2013). One drug that remains on the market is Orlistat, also sold under the name of Alli and Xenical, which works by interfering with nutrient absorption in the gut (Rippe & Angelopoulos, 2012).…”

Section: Treatment Of Obesitymentioning

confidence: 99%

“…One drug that remains on the market is Orlistat, also sold under the name of Alli and Xenical, which works by interfering with nutrient absorption in the gut (Rippe & Angelopoulos, 2012). Orlistat is sometimes chosen to assist with weight loss and diabetes management in obese adults and adolescents (Rippe & Angelopoulos, 2012;Kushner et al, 2013) with the ultimate goal of improving health status.…”

Section: Treatment Of Obesitymentioning

confidence: 99%

See 2 more Smart Citations